161 related articles for article (PubMed ID: 36622182)
1. Antibacterial Activity of an FtsZ Inhibitor Celastrol and Its Synergistic Effect with Vancomycin against Enterococci
Lu X; Wang Y; Guo W; Zhang Z; Hu X; Nie T; Yang X; Li C; Wang X; Li X; Lu Y; Li G; Zhang Y; Sun L; Pang J; You X
Microbiol Spectr; 2023 Feb; 11(1):e0369922. PubMed ID: 36622182
[TBL] [Abstract][Full Text] [Related]
2. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Smith JR; Yim J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
[TBL] [Abstract][Full Text] [Related]
3. Antagonizing Vancomycin Resistance in Enterococcus by Surface Localized Antimicrobial Display-Derived Peptides.
Liu Y; Jia Y; Yang K; Li R; Xiao X; Wang Z
ACS Infect Dis; 2020 May; 6(5):761-767. PubMed ID: 31505930
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.
Wu T; Meyer K; Harrington AT; Danziger LH; Wenzler E
J Antimicrob Chemother; 2019 May; 74(5):1300-1305. PubMed ID: 30753495
[TBL] [Abstract][Full Text] [Related]
5. In vitro Antimicrobial Activity of Fosfomycin, Rifampin, Vancomycin, Daptomycin Alone and in Combination Against Vancomycin-Resistant
Tong J; Jiang Y; Xu H; Jin X; Zhang L; Ying S; Yu W; Qiu Y
Drug Des Devel Ther; 2021; 15():3049-3055. PubMed ID: 34285472
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of oritavancin alone and in combination against vancomycin-susceptible and -resistant enterococci in an in-vivo Galleria mellonella survival model.
Meyer KA; Deraedt MF; Harrington AT; Danziger LH; Wenzler E
Int J Antimicrob Agents; 2019 Aug; 54(2):197-201. PubMed ID: 31034937
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics Of Linezolid-Plus-Fosfomycin Against Vancomycin-Susceptible And -Resistant Enterococci In Vitro And In Vivo Of A
Qi C; Xu S; Wu M; Zhu S; Liu Y; Huang H; Zhang G; Li J; Huang X
Infect Drug Resist; 2019; 12():3497-3505. PubMed ID: 31814738
[TBL] [Abstract][Full Text] [Related]
8. Library Screening for Synergistic Combinations of FDA-Approved Drugs and Metabolites with Vancomycin against VanA-Type Vancomycin-Resistant Enterococcus faecium.
Gargvanshi S; Gutheil WG
Microbiol Spectr; 2022 Oct; 10(5):e0141222. PubMed ID: 35969069
[TBL] [Abstract][Full Text] [Related]
9. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of salicylamide derivatives against vancomycin-resistant enterococci.
Pospisilova S; Michnova H; Kauerova T; Pauk K; Kollar P; Vinsova J; Imramovsky A; Cizek A; Jampilek J
Bioorg Med Chem Lett; 2018 Jul; 28(12):2184-2188. PubMed ID: 29773506
[TBL] [Abstract][Full Text] [Related]
11. In vitro efficacy of fosfomycin-based combinations against clinical vancomycin-resistant Enterococcus isolates.
Tang HJ; Chen CC; Zhang CC; Su BA; Li CM; Weng TC; Chiang SR; Ko WC; Chuang YC
Diagn Microbiol Infect Dis; 2013 Nov; 77(3):254-7. PubMed ID: 24029433
[TBL] [Abstract][Full Text] [Related]
12.
Aktas G
Microb Drug Resist; 2019 Dec; 25(10):1484-1489. PubMed ID: 31343391
[TBL] [Abstract][Full Text] [Related]
13. Assessment of antibiotic resistance and biofilm formation of Enterococcus species isolated from different pig farm environments in Poland.
Grudlewska-Buda K; Skowron K; Bauza-Kaszewska J; Budzyńska A; Wiktorczyk-Kapischke N; Wilk M; Wujak M; Paluszak Z
BMC Microbiol; 2023 Mar; 23(1):89. PubMed ID: 36997857
[TBL] [Abstract][Full Text] [Related]
14. Characterization of clinical enterococci isolates, focusing on the vancomycin-resistant enterococci in a tertiary hospital in China: based on the data from 2013 to 2018.
Zhou W; Zhou H; Sun Y; Gao S; Zhang Y; Cao X; Zhang Z; Shen H; Zhang C
BMC Infect Dis; 2020 May; 20(1):356. PubMed ID: 32517758
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of oritavancin against planktonic and biofilm states of vancomycin-susceptible and vancomycin-resistant enterococci.
Yan Q; Karau MJ; Patel R
Diagn Microbiol Infect Dis; 2018 Aug; 91(4):348-350. PubMed ID: 29678300
[TBL] [Abstract][Full Text] [Related]
16. Modification of 5-methylphenanthridium from benzothiazoles to indoles as potent FtsZ inhibitors: Broadening the antibacterial spectrum toward vancomycin-resistant enterococci.
Zhang N; Song D; Chen W; Zhang S; Zhang P; Zhang N; Ma S
Eur J Med Chem; 2021 Nov; 224():113723. PubMed ID: 34340044
[TBL] [Abstract][Full Text] [Related]
17. Eradication of Vancomycin-Resistant Enterococci by Combining Phage and Vancomycin.
Shlezinger M; Coppenhagen-Glazer S; Gelman D; Beyth N; Hazan R
Viruses; 2019 Oct; 11(10):. PubMed ID: 31623253
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations.
Tsuji BT; Bulitta JB; Brown T; Forrest A; Kelchlin PA; Holden PN; Peloquin CA; Skerlos L; Hanna D
J Antimicrob Chemother; 2012 Sep; 67(9):2182-90. PubMed ID: 22685161
[TBL] [Abstract][Full Text] [Related]
19. Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci.
AbdelKhalek A; Abutaleb NS; Elmagarmid KA; Seleem MN
Sci Rep; 2018 May; 8(1):8353. PubMed ID: 29844350
[TBL] [Abstract][Full Text] [Related]
20. In vitro efficacy of linezolid against vancomycin resistant Enterococci.
Hussain MS; Sattar A; Hussain M
Pak J Pharm Sci; 2018 Sep; 31(5):1853-1857. PubMed ID: 30150180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
